We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NYAX:NASDAQNayax Ltd. Analysis

Data as of 2026-04-21 - not real-time

$63.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Nayax Ltd. (NYAX) is trading at $63, comfortably above its 20‑day SMA of 58.8 and the 50‑day SMA of 57.5, while the 200‑day SMA sits near 50, indicating a strong uptrend. Technical momentum remains bullish with a MACD histogram of 0.51 and a bullish signal line, and the RSI at 59 suggests room for upside without being overbought. The stock holds above a solid support level of 53.05 and is approaching a resistance near 65.7, with volume trending upward, reinforcing short‑term strength. However, volatility is elevated at over 44% for the past 30 days and the beta of 0.80 points to moderate market sensitivity, while the Fear & Greed Index reads “Extreme Greed,” hinting at possible sentiment‑driven risk.
Fundamentally, NYAX delivered a robust 34% revenue growth and maintains a healthy gross margin near 48%, yet profitability is modest with an 8.9% net margin and a free cash flow shortfall. The forward PE of 38.5 far exceeds the industry average of 36.9, and the DCF fair value of roughly $27.7 suggests the market is pricing in significant growth premium, a view supported by recent insider buying and an upgraded Jefferies price target. Upcoming Q4 2025 earnings on March 9 will be a key catalyst, and participation in the NAMA Show underscores continued market engagement. Overall, the stock is technically strong but appears materially overvalued relative to fundamentals, warranting cautious positioning.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD and RSI below overbought levels
  • Proximity to resistance at $65.7 limiting upside
  • Elevated short‑term volatility and sentiment extremes

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue growth and expanding margins
  • Insider buying and upgraded analyst target
  • Upcoming earnings release as a catalyst for momentum

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Persistent overvaluation relative to DCF and peers
  • Sustainable growth but limited free cash flow generation
  • Moderate beta and high volatility implying market risk

Key Metrics & Analysis

Financial Health

Revenue Growth34.30%
Profit Margin8.87%
P/E Ratio65.6
ROE17.93%
ROA3.67%
Debt/Equity146.15
P/B Ratio10.0
Op. Cash Flow$40.3M
Free Cash Flow$-3982875
Industry P/E36.9

Technical Analysis

TrendBullish
RSI59.3
Support$53.05
Resistance$65.70
MA 20$58.82
MA 50$57.51
MA 200$50.00
MACDBullish
VolumeIncreasing
Fear & Greed Index86.04

Valuation

Fair Value$27.72
Target Price$60.63
Upside/Downside-3.77%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.80
Volatility44.21%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.